Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer

Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer

Abstract Background Advances in cancer immunotherapy have generated encouraging results in multiple malignancies refractory to standard chemotherapies. As the use of immune checkpoint inhibitors (ICI) proliferates, the incidence of autoimmune side effects associated with these agents, termed immune...

Full description

Bibliographic Details
Main Authors: James Luke Godwin, Shuchie Jaggi, Imali Sirisena, Pankaj Sharda, Ajay D. Rao, Ranee Mehra, Colleen Veloski
Format: Article
Language:English
Published: BMJ Publishing Group 2017-05-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
PD-1 inhibitor
Nivolumab
Non-small cell lung cancer (NSCLC)
Immune related adverse events (irAE)
Autoimmune diabetes
Diabetic ketoacidosis (DKA)
Online Access:http://link.springer.com/article/10.1186/s40425-017-0245-2

Similar Items

Similar Items